What is Symreboot?

The skin is continuously exposed to bacteria, microorganisms and potential pathogens. To avoid infections or invasion of these pathogenic bacteria the skin has developed multifaceted defense strategies. Beside the physical and chemical barrier of the stratum corneum it includes the constitutive and inductive AMP barrier, which is essential in this context (Harder et al, 2013; Wiesner and Vilcinskas, 2010).

Antimicrobial peptides (AMP) are a diverse and abundant group of molecules. In human skin they serve as first defense line, as they are active against a broad spectrum of Gram positive and Gram negative bacteria, fungi, eukaryotic parasites and/or viruses (Brown and Hancock, 2006).

Probiotics for the skin

The skin microbiome can play a key role in various dermatological conditions. Thus, for instance, atopic dermatitis patients exhibit suppression of various AMPs like cathelicidin or b-defensin or alternations in T-cell homeostasis. The combination of antimicrobial and physical barrier defects likely pushes the dysbiosis (microbiome imbalance) leading to further disruption of the cellular immunity balance (Ong et al, 2002; Palmer et al, 2006; Sakaguchi et al, 2010).

Probiotics have been used in cosmetic applications for diverse purposes. Accordingly, topical application of Lactobacillus plantarum on severe human burns has been described to improve tissue repair and prevent infections (Peral et al, 2009). In addition, Inhibition effects of the Staphylococcus aureus growth with different lactic acid bacteria ferments, including Lactobacillus plantarum, have been observed (Yong et al, 2015).

Lactobacillus plantarum HEAL 19 offers a unique combination that helps to improve the appearance of the skin, while preventing abnormalities. Beside its anti-inflammatory capacity, it has been shown that topical application of this strain provide a combination of supporting the skin’s barrier by induction of various AMPs and reduction of trans-epidermal water loss by inducing the expression of filaggrin, which is essential for the regulation of epidermal homeostasis, in particular water retention (Palmer et al, 2006).

In summary, loss of the skin’s defense barrier may lead to increased transepidermal water loss, which results in dry skin that shown signs of irritation such as redness or flaking. Upregulation of filaggrin and increase of components related to the natural moisturizing factor prevent or alleviate such issues, while anti-inflammatory activity reduces the signs of swelling or redness. Finally, the increase in the expression of AMPs inhibits the growth of pathogenic microorganisms.

Accordingly, the cosmetic use of SymReboot active ingredient serves to :

  • strengthen the skin barrier function
  • reduce transepidermal water loss and increase components related to the natural moisturizing factor
  • induce filaggrin expression
  • provide anti-inflammatory activity, in particular reducing and/or inhibiting inflammatory parameters
  • provide anti-inflammatory activity induced by chemokines and noxae, such as pathogenic microorganisms, air pollutants, ultraviolet radiation and surfactants
  • inhibit the growth, invasion and infection by pathogenic microorganisms, particularly Staphylococcus aureus
  • induce the expression of AMPs
  • maintain, establish and restore a healthy state of the skin microbiome


Baswan SM, Klosner AE, Glynn K, Rajgopal A, Malik K, Yim S, Stern N. Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. Clin Cosmet Investig Dermatol. 2020 Dec 8;13:927-942

Bíró T, Tóth BI, Haskó G, Paus R, Pacher P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci. 2009 Aug;30(8):411-20

Crippa, J.A.; Guimarães, F.S.; Campos, A.C.; Zuardi, A.W. Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age. Front. Immunol. 2018, 9

Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8268-73. 

Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol. 1998;359(1)

Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 2002; 42: 11S–9S.

Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol-recent advances. Chem Biodivers 2007; 4: 1678–92

Mlost J, Bryk M, Starowicz K. Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action. Int J Mol Sci. 2020 Nov 23;21(22):8870. 

Mounessa JS, Siegel JA, Dunnick CA, Dellavalle RP. The role of cannabinoids in dermatology. J Am Acad Dermatol. 2017;77 (1):188–190

Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllõsi AG, Czifra G, Pál B, Ambrus L, Kloepper J, Camera E, Ludovici M, Picardo M, Voets T, Zouboulis CC, Paus R, Bíró T. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest. 2014 Sep;124(9):3713-24.

Rio CD, Millan E, Garcia V, Appendino G, DeMesa J, Munoz E. The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. Biochem Pharmacol. 2018;1 57:122–133

Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chemistry & Biodiversity. 2007;4(8):1729–1743

Sugawara K, Biro T, Tsuruta D, et al. Endocannabinoids limit excessive mast cell maturation and activation in human skin. J Allergy Clin Immunol. 2012;129(3):726–738 

Tüting T, Gaffal E. Chapter 57 – regulatory role of cannabinoids for skin barrier functions and cutaneous inflammation. In: Preedy VR, editor. Handbook of Cannabis and Related Pathologies. San Diego: Academic Press; 2017:543–549

Shopping cart0
There are no products in the cart!
Continue shopping